EMEA-002438-PIP01-18

Key facts

Active substance
Bruton’s tyrosine kinase inhibitor
Therapeutic area
Immunology-Rheumatology-Transplantation
Decision number
P/0020/2019
PIP number
EMEA-002438-PIP01-18
Pharmaceutical form(s)
Tablet
Condition(s) / indication(s)
Treatment of pemphigus
Route(s) of administration
Oral use
Contact for public enquiries
Principia Biopharma, Inc.

Tel.  +1 6504167700
E-mail: info@principiabio.com

Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating